AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Financial Results | Sanofi 2024 Q3 Cumulative Revenue EUR 36655.00 Million Net Income EUR 5107.00 Million
ByAinvest
Friday, Oct 25, 2024 10:00 pm ET1min read
Sanofi(SNY) posted the Q3 of its 2024 financial results on 10/25/2024, reporting total revenue of EUR 36655.00 million in the first three quarters, up 7.04% from EUR 34243.00 million year over year, reporting net income of EUR 5107.00 million in the first three quarters, down 14.80% from EUR 5994.00 million year over year. The EPS is EUR 4.05 in the first three quaters, compare with EUR 4.76 last period.
[Detailed Data]
| Million EUR | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Total Revenue | 14157.00 | 11380.00 | 11118.00 | 12201.00 |
| Cost of Sales | 4085.00 | 3410.00 | 3439.00 | 4048.00 |
| Gross Profit | 10072.00 | 7970.00 | 7679.00 | 8153.00 |
| Total Operating Expenses | 6569.00 | 6578.00 | 6332.00 | 8274.00 |
| Operating Income | 3503.00 | 1392.00 | 1347.00 | -121.00 |
| Net Income | 2844.00 | 1117.00 | 1146.00 | -558.00 |
| Net Income Attributable to Common Shareholders | 2815.00 | 1113.00 | 1133.00 | -555.00 |
| EPS(EUR) | 2.25 | 1.7578 | 0.91 | -0.44 |
[Company Profile]
Sanofi was incorporated under the laws of France in 1994. The company is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The company's activities are organized around the following categories: DUPIXENT, Neurology & Immunology, Rare Diseases, Oncology, Rare Blood Disorders, General Medicines Core Assets and Non-Core Assets, Vaccines, and CHC.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet